The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review by unknown
REVIEW Open Access
The potential role of mitochondrial ATP
synthase inhibitory factor 1 (IF1) in
coronary heart disease: a literature review
Serban Maierean1, Maria-Corina Serban2, Manfredi Rizzo3,4, Giuseppe Lippi5, Amirhossein Sahebkar6,7
and Maciej Banach8,9*
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide, and so the search for innovative and
accurate biomarkers for guiding prevention, diagnosis, and treatment is a valuable clinical and economic endeavor.
Due to a recent findings that the serum concentration of mitochondrial ATP synthase inhibitory factor 1 (IF1) is an
independent prognostic factor in patients with coronary heart disease (CHD), we reviewed the role of this protein
in myocardial ischemic preconditioning, its correlation to plasma high density lipoprotein (HDL), the predictive
potential in patients with CHD, and its interplay with angiogenesis. IF1 has been positively correlated with plasma
HDL-cholesterol, and is independently negatively associated with all-cause and CV mortality in patients with CHD.
However, this conclusion is prevalently based on limited data, and more research is needed to draw definitive
conclusions. IF1 seems to play an additional role in increasing cell vulnerability in oncologic diseases but may also
function as modest inhibitor of angiogenesis in physiological conditions. It has been also explored that IF1 may
rather act as a modulator of other molecules more significantly involved in angiogenesis, especially apolipoprotein
A1 on which the largest effect could be observed. In conclusion, more research is needed to characterize the role
of IF1 in patients with CHD.
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Background
Cardiovascular disease (CVD) is the leading cause of death
worldwide, therefore the search for sensitive biomarkers
for CVD prevention, diagnosis, and treatment seems to be
still critical [1–3]. Mitochondrial ATP synthase, also re-
ferred to in some literature as F1F0-ATPase, is the 5
th
complex of the mitochondrial electron transport chain,
the function of which entails utilization of proton motive
force (PMF) established by the previous complexes in
order to catalyze the energetically-unfavorable ATP syn-
thesis [4]. Under hypoxic conditions, the PMF dissipates
and is unable to propel the activity of ATP synthase. This
leads to a shift in enzyme function, catalyzing the more
energetically favorable hydrolysis of ATP [4]. In 1995,
Vuorinen et al. first investigated the role of F1F0-ATPase
in preconditioning of rats’ hearts to ischemia, demonstrat-
ing that the inhibition of this enzyme led to release of
cytosolic ATP and to the improvement of time-averaged
energy state of the heart during subsequent episodes of
prolonged ischemia [5]. A successive study convincingly
suggested that mitochondrial ATP synthase inhibitory
factor 1 (IF1) is the molecule responsible for ischemic pre-
conditioning (IP) by inhibiting the F1 subunit of the F1F0
complex during hypoxic states [6]. It was also noticed that
larger mammals, especially those with slower heartbeats,
experienced a more pronounced release of ATP due to hy-
drolysis [6]. Further investigation revealed that up to 80%
of cytosolic ATP hydrolyzed during ischemic episodes in
some species can be attributed to the activity of F1F0-
ATPase alone [7], and that overexpression of IF1 pro-
tected from ischemic damage [8]. After discovery that
mRNA, which is transcribed into the beta-chain of the F1
subunit of the F1F0-ATPase (the site of action of IF1), is
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transcriptionally active in hepatocytes [9], Martinez et
al. demonstrated that such ectopic beta-chains are
found on cell surface of hepatocytes, and that they act
as apolipoprotein A-I (apoA-I) receptors, thus mediating
holo-endocytosis of high-density lipoprotein cholesterol
(HDL-C) [10]. This finding paved the way to uncover
many potential clinical implications, such as the possible
use of these ectopic beta-chains as potential drug targets
in patients with, or at risk of developing coronary heart
disease (CHD). In light of these findings, Genoux et al.
[11] performed a cross-sectional study for evaluating the
correlation between serum concentrations of exogenous
ecto-F1-ATPase inhibitor, IF1, HDL-C and triglycerides. It
was hence observed that serum IF1 concentrations were
directly correlated with HDL-C values and negatively as-
sociated with triglycerides [11]. Subsequent research by
the same team of scientists confirmed that serum IF1 con-
centration is positively associated with HDL-C concentra-
tions and negatively with CHD [12], and finally that IF1
has an independent and positive association with long-
term prognosis of CHD [13]. These findings bring about
many potential implications in prevention of CHD and
management of patients with established disease. IF1 has
also been studied in the context of angiogenesis [14–16].
Provided that IF1 interplays with angiogenesis, a relation-
ship may also be put forward between the number of col-
lateral arteries in the hearts of patients with different
baseline IF1 values [17].
The purpose of this review is to aggregate and critically
analyze the areas where IF1 might be implicated in cardio-
vascular (CV) health, to assemble the bulk of knowledge
currently available on this topic, and discuss areas where
future research would be of great interest and importance
for increasing the knowledge about the vast potential of
IF1. This review will hence focus on the role of IF1 in
curbing cellular ischemic injury, on its relationship with
HDL-C, its predictive potential in CHD and its potential
interplay with angiogenesis.
Search strategy
We carried out an electronic search on electronic scien-
tific databases [MEDLINE (1966-14th August 2016),
EMBASE and SCOPUS (1965-14th August 2016), DARE
(1966-14th August 2016)], and Web of Science Core
Collection (up to 14th August 2016). Abstracts from na-
tional and international meetings were also searched.
When necessary, the relevant authors were contacted to
obtain additional information. The main search terms
were: angiogenesis, atherosclerosis, arteriosclerosis, endo-
thelial dysfunction, cardiovascular, cardiovascular disease,
coronary heart disease, CHD, CVD, high density lipopro-
tein, inhibitory factor 1, ischemic, mitochondrial ATP syn-
thase. The main inclusion criterion was the existence of
relatively strong data from studies, trials and meta-
analyses investigating the role of IF1 in lipid disorders,
angiogenesis and cardiovascular function.
Ischemic cellular damage and myocardial ischemic
preconditioning
One of the more investigated roles of IF1 is its capabil-
ity to reduce ATP hydrolysis when the cell is challenged
by hypoxia [7]. The binding of IF1 to ATP synthase is
promoted by a decrease in both membrane potential
and mitochondrial matrix pH [7]. It is now clear that
IF1 is directly implicated in mitigating the generation
of ADP from ATP by means of hydrolysis, as reflected
by the relationship between ATP production and IF1
concentration, as well as by its species-specific affinity
for the beta-subunit of F1 [6]. In order to verify
whether IF1 may directly inhibit the hydrolysis of ATP
mediated by ATP synthase, Rouslin et al. [6] pre-
treated animals’ hearts with the uncoupling agent car-
bonyl cyanide p-trifluoromethoxyphenulhyobrozone
(FCCP), which acts through dissolution of the PMF.
Their most relevant finding was that the rabbit cardio-
myocytes, whose mitochondria housed relatively higher
concentrations of high-affinity IF1, were more effective
at preserving ATP during short bouts of ischemia than
rat and pigeon hearts, whose cardiomyocytes contained
lower levels of high-affinity IF1 and a full complement
of lower-affinity IF1, respectively [6]. However, after
30 min of ischemia, all pre-treated hearts contained al-
most undetectable concentrations of ATP [6]. This
evidence is supported by research showing that HeLa
cells with permanent IF1 knockout have a ~30% lower
concentration of ATP under ideal growing conditions
compared to non-knockout cells [18]. This seems to
suggest that antagonism of ATP hydrolysis by IF1 not
only functions when the cell is challenged by ischemia,
but also under physiological conditions [18]. However,
when exposed to ischemia under normal conditions (i.e.,
not under the effects of uncoupling agents), Hassein et al.
put forward the hypothesis that the bulk of observed
beneficial effects of IF1 are maybe not directly due to in-
hibition of enzymatic activity of ATP synthase, but rather
to inhibition of proton conductivity of ATP synthase [7]
achieved by physically blocking ATP synthase’s H +
−channel [19]. Preserving the proton electrochemical gra-
dient in the mitochondrial membrane inhibits the reversal
of ATP synthase, and also limits reperfusion damage [7].
They also suggested that IF1 may play a role in increasing
the coupling efficiency of the complex [20], as in Luft’s
disease, which is characterized by mitochondrial uncoup-
ling [7]. By limiting reperfusion damage and helping
maintain the PMF, IF1 could potentially be implicated in
post-ischemic recovery, although this remains to be fur-
ther elucidated [7].
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Regardless of the specific mechanism of action of IF1
in reducing ischemic injury, Genoux et al. prospectively
studied 577 males with stable CHD for a median follow-
up of 11 years, and observed that patients with CHD
who died had lower serum concentration of IF1 and
higher values of N-terminal pro-brain natriuretic peptide
(NT-proBNP) and high sensitivity troponin T (hsTnT)
(i.e., two biomarkers associated with myocardial injury)
compared to those who survived [13].
Interestingly, another research conducted by Fujikawa et
al. showed that mitochondria of HeLa cells with a
permanent IF1 knockout seemingly generate greater PMF
and produce almost double the amount of reactive oxygen
species (ROS) as control cells under ideal growth condi-
tions (i.e. not under ischemic stress) [18], a finding that
was then confirmed in a separate research [21]. These re-
sults should raise interest in the possibility of increased
baseline cellular turnover in persons who express lower
levels of IF1, secondary to mitochondrially-induced apop-
tosis due to the increase in local ROS.
Despite many findings relating to the involvement of
IF1 in releasing ATP during ischemia, its role in myocar-
dial ischemic preconditioning remains controversial. In
1990, Das and Harris proposed that the bidirectional
functionality of ATP synthase is modulated by a regula-
tory protein [22]. Afterwards, another study reported
that preconditioned rat hearts displayed a sustained ATP
synthase inhibition, thus benefiting the rats upon subse-
quent ischemic challenges [5]. Opposite results were ob-
tained in another study focused on inhibition of F1F0-
ATPase of canine hearts, which showed that although
energy sparing is a feature of ischemic preconditioning,
ATPase inhibition is not the most likely explanation for
this phenomenon [23]. Yet a subsequent study was car-
ried out, reporting that the baseline activity of F1F0-
ATPase was not significantly different in preconditioned
versus control mitochondria, but the time required for
the enzyme to reach steady-state was increased in the
preconditioned mitochondria before sustained ischemia
[24]. The authors concluded that if ATP synthase is sup-
posed to play a role in ischemic precondition, this might
only be modest [24]. Therefore, the exact role of IF1 in
ischemic preconditioning remains controversial. More
clinical potential exists in understanding the extent to
which IF1 can help patients vulnerable to ischemic injury,
especially those at higher risk of developing a myocardial
infarction.
Correlation between IF1, HDL and CHD
Despite the fact that F1F0-ATPase is a mitochondrial
protein, the F1 catalytic subunit of this enzyme was
found to be also present on the plasma membrane of
rat hepatocytes [9], herein conventionally referred to as
ecto-F1-ATPase. Interestingly, ecto-F1-ATPase was shown
to mediate holo-HDL endocytosis in hepatocytes via
the interaction between the beta-subunit of F1 and
apoA-I of HDL particles [10], a distinct pathway from
that entailing the more important scavenger receptor-
B1 HDL-uptake, according to which the protein com-
ponents of HDL are not endocytosed [25]. Martinez et
al. have recently explained this pathway to function
roughly as follows [26] (Fig. 1): (1) the apoA-I protein
moiety of an HDL particle binds to the beta-subunit of
ecto-F1-ATPase; (2) extracellular ADP, which is nor-
mally kept in balance by ecto-F1-ATPase and adenylate
cyclase, increases by activation of ecto-F1-ATPase; (3)
the increased concentration of extracellular ADP activates
P2Y13-receptor, a G-protein coupled receptor; (4) in turn,
this activates the guanosine triphosphatase (GTPase)
RhoA via phosphorylation, which then activates Rho-asso-
ciated kinase I (ROCK I), also via phosphorylation; (5) the
cell finally undergoes cytoskeletal reorganization, thus
resulting in endocytosis of HDL [26].
The inhibition of ecto-F1-ATPase seems to only affect
HDL uptake, with no effects on the transport of LDL
[26]. Unlike in myocardial cells, IF1 binding to F1 is not
improved by decreased pH [26]. This may suggest that
the F0 subunit of the F1F0-ATPase, which is missing on
cellular plasma membranes [10], might perhaps be the
determinant of whether the complex is used for HDL
transport or cell survival during hypoxic conditions,
although this remains a mere speculation. It has also
been observed that ecto-F1-ATPase is present on the
surface of endothelial cells where, along with P2Y12,
mediates HDL transmigration. Although the physio-
logical and clinical significance of this mechanism is still
unclear, it seems reasonable to suggest that ecto-F1-
ATPase activation might play a role in either accumula-
tion of HDL in foam cells and enhancement of reverse
cholesterol transport (RCT) [26]. Inhibition of ecto-F1-
ATPase by IF1 should then result in an increase in total
circulating HDL-C by reducing its endothelial uptake.
Although a strong correlation exists between IF1 and
HDL-C [11–13], the existence of a causal relationship
has not been definitely proven; neither is clear whether
or not increased HDL resulting from exogenous ecto-F1-
ATPase inhibition (i.e. via pharmacotherapy) would finally
translate into significant clinical advantages. Perhaps,
while IF1 increases plasmatic HDL concentrations by re-
ducing its hepatic uptake, inhibition of the same receptors
at the endothelial level might also reduce the degree of
HDL transmigration, which might reduce the benefits of
the increased plasma HDL concentration.
From a clinical perspective, Genoux et al. published a
series of studies aimed to investigate the association be-
tween serum IF1, plasma HDL, and their correlation
with the prevalence of CHD and patient survival. Inter-
estingly, the serum concentration of IF1 (medians of
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0.43 ± 0.13 mg/L, p < 0.001 [cases], and 0.53 ± 0.15 mg/
L, p < 0.001 [controls]) was found to be positively asso-
ciated with plasma HDL-C (r = 0.27, p < 0.001) and
apoA-I (r = 0.28, p < 0.001) and negatively with triglyc-
erides (r = −0.23, p < 0.001) (case-control study with
648 cases and 669 controls, males) [12]. These findings
were then confirmed by measurements carried out in pre-
vious (cross-sectional study with 100 normolipidemic
male participants) [11] and later (prospective cohort with
577 male participants suffering fromcoronary artery dis-
ease [CAD]) [13] studies by the same team of authors.
The mean serum IF1 concentration was also found to be
lower in patients with CHD (0.43 mg/L, p < 0.001) than in
control subjects without CHD (0.53 mg/L, p < 0.001), and
was significantly correlated with CHD after adjusting for
plasma HDL and apoA-I (p < 0.001) [12]. A higher CHD
risk reduction was noticed in patients with low HDL and
high IF1 (69% lower odds ratio (OR = 0.31, 95% CI [0.20,
0.48], p < 0.001)) than in patients with median values of
HDL and IF1. Patients with high HDL and low IF1 also
exhibited a reduced risk of CHD (OR = 0.24, 95% CI [0.15,
0.37], p < 0.02). Expectedly, the presence of elevated con-
centrations of both HDL and IF1 conferred an even larger
risk reduction (OR = 0.14, 95% CI [0.09, 0.21], p < 0.001);
patients with low values of apoA-I and high concentration
of IF1 had a comparable risk reduction (OR = 0.32, 95%
CI [0.20, 0.51], p < 0.001), whereas those with elevated
values of both had the greatest risk reduction (OR = 0.10,
95% CI [0.07, 0.15], p < 0.001). However, patients with
only apoA-I elevated displayed a similar risk [OR = 0.14,
95% CI [0.09, 0.21], p < 0.001) [12]. The finding that in-
creased apoA-I conferred a similar risk reduction of CHD
as both elevated apoA-I and IF1, while the same did not
hold true for HDL and IF1, is interesting and merits
further investigation and confirmation. As IF1 is a com-
petitive antagonist of apoA-I [10], it seems reasonable to
suggest that a high apoA-I concentration may reflect an
enhanced production to compensate for a high baseline
IF1 value, so not translating to improved outcomes. This
hypothesis remains to be investigated, however.
In their most recent research, Genoux et al. measured
serum IF1 concentration in 577 males with stable CHD,
and found that both cardiovascular and all-cause mor-
tality were lower for patients in the highest quartile of
IF1 (hazard ratio [HR] 0.50, 95%CI 0.28–0.89, and 0.55,
95%CI 0.38–0.89, respectively), whereas death rate was
virtually identical across quartiles of HDL [13]. While sur-
prising, this finding had been confirmed by additional re-
search showing that only the large HDL subfraction
(measured using the Lipoprint® system) [27], but not total
HDL, is associated with decreased mortality in patients
with CHD [27, 28]. Unlike HDL, IF1 does not seem to be
related to blood pressure, nor with alcohol consumption
[13], which slightly differentiates it from traditional car-
diovascular risk factors. Contrarily, IF1 was found to be
positively correlated with left ventricular ejection fraction
(LVEF) and negatively associated with severity of CAD)
[13]. Overall, IF1 seems a better marker for predicting
Fig. 1 The pathway of ecto-F1-ATPase-mediated holo-HDL endocytosis. (1) ApoA-I, found on the HDL molecule, binds to the beta-subunit of the
ecto-F1-ATPase of a hepatocyte; (2) This binding activates ecto-F1-ATPase, causing it to increase the production of ADP from ATP; (3) With the
extracellular concentration of ADP increased, P2Y13, a G protein-coupled receptor, is activated, phosphorylating the GDP molecule found on the
alpha-subunit of the G Protein. This phosphorylation activates the G protein, releasing it from its beta and gamma subunits; (4) The G Protein then
activates RhoA by phosphorylation, causing the G Protein to become inactive where it will return to join its beta and gamma subunits on the inner
plasma membrane. Activated RhoA will then donate a phosphate group to ROCK1, activating the protein; (5) ROCK1 then drives the cytoskeletal
modifications necessary for holo-HDL endocytosis
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outcomes in patients with CHD than total HDL, although
larger prospective studies may be needed to validate this
conclusion [29]. Moreover, additional research should be
planned to explore the relationship between IF1 and other
risk factors of CVD, especially physical activity, body mass
index and waist circumference. Studies of homozygous
versus heterozygous twins would also be beneficial in
identifying the most significant determinants of IF1 con-
centration. Finally, although higher IF1 values correlate
with a lower risk of CHD and better outcomes in patients
with CHD, it remains unclear whether therapeutically
driven enhancement of IF1 concentration may generate
comparable outcomes.
IF1 and angiogenesis
From a physiological perspective, evidence was brought
that IF1 may act as a weak inhibitor of angiogenesis,
whereas a more effective role has been shown in pro-
tecting endothelial cells from hypoxic damage, thus
mirroring its function in mitochondria [15]. Burwick et
al. compared the effect on angiogenesis in vitro on hu-
man umbilical vein endothelial cells (HUVEC) of IF1,
angiostatin and cycloheximide [15]. An IF1 concentra-
tion of 10 μg/mL was found to have a 20% inhibitory
effect on endothelial cell proliferation, whereas inhib-
ition was 60% using cycloheximide, a well-known pro-
liferation inhibitor [15]. Earlier results from the same
team of scientists reported that angiostatin was able to
inhibit endothelial cell proliferation by 57% [30]. Al-
though IF1 appears to possess a certain inhibitory po-
tential on endothelial cell proliferation, its modulatory
capacity should be considered globally modest. In fact,
unlike cycloheximide, IF1 is not effective in inhibiting
endothelial cell tube formation [15]. Interestingly, Bur-
wick et al. noticed that angiostatin competes with and
thereby antagonizes IF1 for the active site of cell sur-
face ATP synthase, ultimately reducing its ability to
conserve ATP at low pH. Whether angiostatin and IF1
may be competitive inhibitors remains to be elucidated
[15]. It was hence hypothesized that IF1 may be a pro-
tective factor for endothelial cells under condition of
low pH such as in tumor microenvironment, and that
inhibiting ATP hydrolysis alone may be insufficient for
preventing angiogenesis, which actually requires inhib-
ition of ATP synthesis [15].
Despite available evidence that IF1 might not be a
significant modulator of angiogenesis, at least directly,
the results of a recent study suggest that it is instead an
antagonist to apoA-I, which was found to promote
angiogenesis in human endothelial progenitor cells
(hEPC) [16]. This study evidenced that hEPCs express
ATP synthase on the surface of their plasma membrane,
and like in hepatocytes, these cells bind apoA-I. It was
also observed that 50 μg/mL of apoA-I was a sufficient
concentration to enhance cellular proliferation by 14.5%
(p < 0.001), and the number of branch points and length
of tubules by 31% (p < 0.01) compared to controls [16].
The addition of IF1 and of the known inhibitor oligomycin
separately, completely inhibited these effects, whereas in-
hibition of the scavenger receptor class B type I (SR-BI)
alone only partially reduced the angiogenic effects of
apoA–I [16].
From a clinical perspective, recent evidence was
brought that overexpression of IF1 in hepatocellular
carcinoma (HCC) is a poor prognostic indicator, and
that this cancer displays a larger degree of angiogenesis,
more pronounced active epithelial-mesenchymal transi-
tion, and more frequent metastasis than HCC tumors
that express normal levels of IF1 [14]. Silencing of IF1
expression resulted in the attenuation of epithelial-
mesenchymal transition and invasion of HCC cells [14].
The likely biochemical pathway to explain these obser-
vations entails that IF1 may promote overexpression of
Snail (a Zinc-Finger transcription factor that leads to a
downregulation of E-cadherin [31], allowing angiogen-
esis during embryonic development ultimately medi-
ated by epithelial-mesenchymal transition [32] and of
vascular endothelial growth factor (VEGF) through nu-
clear factor-kappa B (NF-κB) signalling. NF-κB is then
thought to generate a positive feedback loop with IF1
by direct upregulation of the protein [14].
In conclusion, despite the evidence that IF1 might be
somehow involved in the modulation of angiogenesis,
additional research is needed to objectively confirm
these preliminary findings. Based on data presented in
this review, it seems reasonable to conclude that IF1
may only promote angiogenesis in neoplastic conditions
[14]. It is possible, however, that it may act as an indir-
ect modulator of angiogenesis by interplaying with
other proteins such as apoA-I [16].
Conclusions
Although IF1 does not apparently play a key role in
myocardial ischemic preconditioning, the available
evidence suggests that it may be effective in limiting
cellular damage during short bouts of ischemia and
reperfusion. Additional research is hence needed to
better understand the relationship between blood IF1
concentration and outcomes in acute coronary events.
In patients with stable CHD, higher concentrations of
serum IF1 seem to be associated with better outcomes,
but new studies should be planned to verify whether a
therapeutically driven increase of serum IF1 may gener-
ate comparable (favorable) outcomes in patients with
stable CHD. Regarding the involvement of IF1 in angio-
genesis and cardiovascular health, again no definitive
conclusions can be drawn, mainly due to the hetero-
geneity of the available studies. Nevertheless, IF1 seems
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to be involved in both promoting and inhibiting angio-
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